Redeye: Medivir - Birinapant enters a new indication
The investigator-led study in patients with HSNCC has enrolled the first patient. In the study, birinapant is being evaluated in combination with radiation therapy. We estimate peak sales potential in this setting of about USD 300m with an LOA of 6%. The HSNCC indication adds SEK 1 to our valuation of Medivir, which is being raised to SEK 34.
Read more and download the research update: http://bit.ly/2IGrXu6
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/